Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda Pharmaceutical Company and Sage Bionetworks, a biomedical research organisation, have formed a four-year research alliance that will focus on discovering effective therapeutic targets for central nervous system (CNS) disease.
Subscribe to our email newsletter
Sage Bionetworks said that a team of network biologists, systems biologists, statistical geneticists and computational biologists use coherent datasets containing clinical, genetic and molecular layers of information to virtually build advanced predictive models of disease.
Using its integrated genomics methods, Sage’s scientists are expected to build a predictive model and identify key regulatory genes and predictive biomarkers in patients with CNS disease.
Takeda and Sage Bionetworks said that scientists at the two companies will then work together to discover and prioritise the targets that hold the greatest potential for molecular intervention.
As per the terms of the agreement, Takeda will provide more than $3.6m over four years in research funding and fees.
Sage Bionetworks president Stephen Friend said that they were excited about the great synergy between Sage’s network biology technology and Takeda’s expertise in pharmaceutical research and development.
Takeda Pharmaceutical Research Division head and general manager Paul Chapman said that Sage Bionetworks’ technology offer the potential for Takeda to understand currently unknown disease mechanism.
"We view this collaboration as an opportunity to further Takeda’s goal of identifying targets for new therapeutics to treat the serious effects of CNS diseases," Chapman said.